Founded by Princeton scientists and drug-development leaders, Doylestown-based Evrys Bio develops antiviral therapies that target host-cell SIRT2 rather than the virus itself. Its small-molecule approach is designed to work across a broad spectrum of viral infections while limiting the development of drug resistance, with EV-100 identified as its clinic-ready lead asset.
Benevira, IncBenevira is a privately owned synthetic biology company developing and manufacturing antiviral biologics, therapeutics, and consumer health products. Its technology targets viral evolutionary bottlenecks to create sustainable treatments and prophylactics for emerging and established viral diseases, including COVID-19 and influenza.NEW YORK, NY
Intervir LLCIntervir LLC is a pharmaceutical manufacturing company focused on discovering novel antiviral therapeutics.PHILADELPHIA, PA
Sator Therapeutics LLCCleveland-based Sator Therapeutics develops naturally occurring, non-pathogenic oncolytic viruses intended to selectively kill cancer cells in hard-to-treat tumors. Its preclinical platform combines a library of nearly 30 human enterovirus strains with systemic delivery, sequential dosing, companion diagnostics, and a patented dendritic-cell carrier. The company’s approach is protected by four issued U.S. patents and a Japanese patent, while its lead mesothelioma program advances toward formal clinical development.CLEVELAND, OH
SIGA Technologies, IncSIGA Technologies develops medicines for emerging infectious diseases, with its core product TPOXX serving as the first U.S. FDA-approved antiviral treatment specifically indicated for smallpox. The company’s work centers on preparing governments and public-health partners for outbreaks, while its development operations in Corvallis support studies of additional TPOXX uses and formulations. SIGA reports 50 employees, products sold in more than 30 countries, and more than $1 billion in cumulative government procurement orders.NEW YORK, NY